Correction to Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial (The Lancet Oncology (2021) 22(1) (74–84), (S1470204520305349), (10.1016/S1470-2045(20)30534-9))

摘要

? 2022 Elsevier LtdToi M, Imoto S, Ishida T, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021; 22: 74–84—In this Article, minor typological errors in the Summary, Methods, Figure 2, Results section, and Tables have been corrected. The appendix has also been updated. These corrections have been made to the online version as of Sept 26, 2022.